Stock BMEA BIOMEA FUSION, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Market Closed - Nasdaq
Other stock markets
 03:59:47 2024-06-04 pm EDT 		5-day change 1st Jan Change
10.94 USD -0.09% Intraday chart for Biomea Fusion, Inc. -6.09% -24.66%
May. 30 Biomea Fusion Completes Enrollment of First 3 Dose Expansion Arms of Diabetes Trial MT
May. 30 Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GL
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
GL
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
GL
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
GL
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
AQ
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
GL
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle
AQ
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
GL
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
GL
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study with BMF-219
AQ
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
GL
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity in First Complete Responder from Ongoing Phase I Study of BMF-219 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
AQ
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks off Treatment in Ongoing Phase II Study of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation
AQ
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMEA Stock
  4. News Biomea Fusion, Inc.
  5. Press Releases